Brainstorm Cell Therapeutics Inc.
BCLI
$1.00
$0.011.01%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -81.24% | 12.61% | -15.57% | 27.45% | -1.36% |
| Total Depreciation and Amortization | 24.32% | -22.92% | 0.00% | -5.88% | -1.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,630.08% | -58.70% | 105.10% | -68.79% | -29.85% |
| Change in Net Operating Assets | -3.77% | -51.89% | 65.71% | 169.30% | -348.49% |
| Cash from Operations | 32.20% | -78.38% | 32.85% | 68.53% | -114.71% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -51.89% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.46% | -- | -- | -90.66% | 389.05% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -70.02% |
| Cash from Financing | -28.16% | 60.26% | 149.20% | -88.41% | -12.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 104.29% | -275.00% | 105.07% | 1.50% | -155.05% |